MGC Pharmaceuticals has announced it has completed a £5.5m capital raise which will go toward progressing its clinical pipeline.
European-based biopharma company specialising in the production of phytomedicines, MGC Pharmaceuticals, says the raise was supported by a mix of institutional and family office investors from the UK and USA, comprising both new and existing shareholders.
Since listing on the LSE in February, the company has been focused on developing its clinical pipeline and taking steps towards market authorisation for its products. Specifically, it has been working on achieving Emergency Use Authorisation for CimetrA, a nanoparticle micellar formulation that has demonstrated to be an effective treatment for mild and severe cases of COVID-19 in preclinical and clinical trials.
Co-founder and managing director, Roby Zomer, commented: “This latest fundraise will provide MGC Pharma the capital required to continue the excellent progress we have made this year with our clinical pipeline.
“In the last few months, we have made real progress on advancing CimetrA towards Emergency Use Authorisation in key territories, all while achieving record revenue figures on our existing products, including ArtemiC. With the completion of our CimetrA Production Facility in Malta now awaiting its fit-out, we will soon be in a position to meet the expected demand for this product when we achieve Emergency Use Approval in key territories and really make a difference to the treatment of COVID-19 patients.
“By looking for Emergency Use Approval of CimetrA in the USA (with our partner AMC) and India, two of the largest pharmaceutical markets in the world, amongst others, we are showing our belief in the product, and our ambition for MGC Pharma.
“The benefits of CimetrA are being shown in trials across the world. As more variants emerge, we believe that CimetrA will be able to treat the pathophysiological mechanism of the disease. It is more important than ever that we accelerate the Emergency Use Authorisation process in territories across the globe, to make sure that all patients have access to CimetrA. Everyone at MGC Pharma is ready to build on the excellent work that has been done so far, and to deliver for our shareholders and for patients globally.”
To achieve Emergency Use Authorisation for CimetrA, MGC Pharma has received approval for a dosage study by the Rambam Medical Center’s Ethics Committee in Israel. Funds from the placing will go to completing the study, recruiting patients in territories across the globe. In conjunction with this, MGC Pharma will also be looking to fund Emergency Use Authorisation applications and their associated testing requirements for other territories in Central and Eastern Europe, and Central Asia.
Additionally, the proceeds will also be used for further clinical trials in the USA of the medicine CannEpil, MGC Pharma’s phytocannabinoid-derived IMP designed to treat drug-resistant epilepsy,
The placement shares will be issued at 2 pence each, representing a 13 per cent discount from the closing price on 29 November 2021, and once issued will represent approximately 10 per cent of MGC Pharma’s ordinary shares.
Turner Pope acted as sole and exclusive lead manager and bookrunner for the placing into the London market.
Industrial hemp in Europe driving global market growth
A new report has projected the market to exceed $310m by 2027.
A new report has attributed the growing hemp market in Europe as a driving factor of global growth.
A once under-utilised crop, hemp is now seeing strong growth thanks to the demand for alternative products. Food, drink and personal care products are driving the growth of the industrial hemp market.
A new report from Global Market Insights has highlighted government regulations and policies associated with the legalisation of cultivation, as well as escalating demand for hemp products as a main driver of the market.
The market size was over USD$205m (~£151.09m) in 2020 and is projected in the report to reach $310m by the end of 2027.
Fibre and seeds
Hemp is utilised extensively in the pulp and paper industry as it is a considerably more sustainable crop than wood. This is due due to the fact its does not need bleaching produces more pulp per acre, offers enhanced paper strength, and utilises chemicals that are less toxic compared to wood paper.
The report highlights that government regulations seeking to limit wood harvesting and the associated harmful consequences of wood pulp and paper production, are likely to foster product uptake.
It speculates the segment will see robust growth to attain a valuation of more than $70.5m by 2027.
The hemp seeds segment is slated to surpass a valuation of around $74.5m by 2027 under food and beverages application, due to their wide use in supplements, such as protein powder and meal replacement bars and snacks.
The report has attributed a proliferating industrial hemp market in Europe as well as mounting product application in automotive manufacturing as additional drivers of growth in the global market.
It notes that the Europe industrial hemp market is projected to progress at a CAGR of approximately 5.5 per cent over the forecast period to surpass a valuation of $80.5m.
Growing consumer awareness of the plant’s therapeutic effects has also boosted product demand in recent years, according to the report.
To read the full report please visit: https://www.gminsights.com/roc/3306.
Canxchange launches new trading system for the cannabis market
Canxchange is introducing more transparency, liquidity and efficiency to the growing cannabis market through its new platform.
Canxchange, the leading physical hemp and CBD exchange, has launched a new electronic trading system for the cannabis market to simplify sourcing, buying and selling.
The new Canxchange trading system is the result of more than one year of product development and engineering work.
The platform provides electronic trading, market surveillance tools, price discovery options, data and features to enhance daily business and transactions for Canxchange members.
CEO and co-founder of Canxchange, Alex Arkentis, commented: “As we continue to improve and upgrade Canxchange, our main objective is to facilitate our members based on their feedback and market needs.
“We have spent the past two years listening closely to what our members are looking for and educating ourselves on what the industry lacks.
“With the launch of our latest platform, now our traders can focus on their strategic priorities, and rely on Canxchange to handle everything else.”
The platform has been designed based on market and member feedback, to simplify the process of sourcing, buying and selling.
New platform features include:
- Simplified processes and more powerful user experience
- Production and distribution procurement contracts
- Market surveillance tools
- Data and pricing analysis
It will leverage the expertise and proven track record of Canxchange, a European leader in physical cannabis trading with a reputation for world-class technology, cutting-edge service solutions and trading reliability and efficiency.
Canxchange has said that it plans to continue developing its operation and network of users globally, following the success seen by adopters of the platform across Europe. The company aggregates farmers, producers and extractors and a wide range of industries under one roof; offering a wide network of vetted businesses to its members.
Oxford Cannabinoid Technologies sees positive progression
Oxford Cannabinoid Technologies Holdings has begun 2022 with a positive start and has announced a new date for the start of its Phase I trial.
Oxford Cannabinoid Technologies Holdings (OCTP) had a positive year in 2021 and has begun 2022 on the same foot.
The company has reported financial results for the six-month period ending 30 November 2021 in line with expectation, during which approximately £920k of research and development costs were incurred. The costs were primarily on lead drug candidate OCT461201, which accounted for approximately £604k of the total.
OCTP and its subsidiary, Oxford Cannabinoid Technologies Ltd. (OCT) had total cash reserves of approximately £12m and no debt, having repaid a Government bounce-back loan of £50k in full. The group has noted that progress is being made on all four of its programmes.
CEO, John Lucas, commented: “We are pleased with the progress made on all four programmes during the Period. OCTP remains on time, on budget and in line with our expectations.
“This was a busy period for the company following the successful listing in May.
“During the first half, we made good strides across the board and, as such are excited by the potential as the year progresses and look forward to updating the market further in due course.”
2021 also saw the company enter into agreements with leading global cannabis company Canopy Growth Corporation, as well as with Aptuit (Verona) SRL, a subsidiary of Evotec SE (Evotec).
OCTP’s agreement with Canopy Growth Corporation gives the company an exclusive license to Canopy Growth’s cannabinoid library. This includes 335 derivatives and 14 patent families. Oxford Cannabinoids has now begun screening the drug-like compounds in multiple therapeutic areas, including pain, neurology, immune-inflammation and oncology.
OCTP is working with Dalriada Drug Discovery to screen the compounds and Oxford Cannabinoid Technology’s (OCT) existing proprietary cannabinoid library. Dalriada previously designed, synthesised, and experimentally tested all of the compounds in the Canopy library and as such, OCT will be able to leverage Dalriada’s existing knowledge and experience as it continues its experimental research.
The aim is to identify two drug candidates for pre-clinical development by the end of 2022.
A further agreement with Oxford Stemtech announced in November 2021, is supporting the research and development for all the company’s drug development programmes, with a particular focus on programmes three and four.
Stemtech’s “pain-in-a-dish” model replicates human pain using stem cells from volunteers that are re-programmed into pain neurons. This agreement also marks an evolution of OCTP’s relationship with Oxford University Professor, Dr Zameel Cader.
OCT also entered into a £2.6m contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE (Evotec) in July 2021.
The company has confirmed in its update that the planning phase has been completed and “wet-work”, manufacturing process development and crystallisation development have now been initiated.
It has also confirmed that it is anticipated that Evotec will provide the OCT with a submission-ready regulatory document and an approved batch of drug product that is ready for Phase 1 clinical trials by Q1 2023.
Originally set to commence in Q3 2022, the date for the trial has been moved to Q1 2023 due to technical issues requiring additional optimisation of the crystal development for scale-up manufacturing, which has been now successfully implemented.
The OCT board has stated this will not impact time to Phase II clinical trials, there is no material cash flow impact and the time to market is currently anticipated to remain the same.
The agreement with Voisin remains on track according to the update with a roadmap ti clinical development having been generated to support the ongoing pre-clinical package for programme one.
Voisin has also undertaken activities in preparation for the commencement of the Phase I clinical trials and is providing the Group with regulatory support to address immediate priorities for filing and registration of Programme 2’s metered-dose inhaler in the UK and US market.